Emma Croushore

Dr. Emma Croushore

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
DMDarlene Mitrano
Darlene Mitrano
SHSam E. Houle
Sam E. Houle
PPPatrick Pearce
Patrick Pearce
RQRicardo M. Quintanilla
Ricardo M. Quintanilla
BLBlakely K. Lockhart
Blakely K. Lockhart
LWLisa Smith Webb
Lisa Smith Webb
Alzheimer’s disease (AD) is an incurable neurodegenerative disease in which the risk of development increases with age. People with AD are plagued with deficits in their cognition, memory, and basic social skills. Many of these deficits are believed to be caused by the formation of amyloid-β plaques and neurofibrillary tangles in regions of the brain associated with memory, such as the hippocampus. However, one of the early, preclinical symptoms of AD is the loss of olfactory detection and discrimination. To determine if a mouse model of AD expresses the same olfactory dysfunction seen in human AD, 3xTg-AD mice were given a buried food test and, unlike previous studies, compared to their background and parental strains. Results showed that over 52 weeks, the 3xTg-AD mice took significantly longer to find the buried food than the control strains. The olfactory bulbs of the 3xTg-AD mice were removed, sliced, and stained using Congo red for histological analysis. Amyloid deposits were observed predominantly in the granule layer of the olfactory bulb beginning at 13 weeks of age in 3xTg-AD mice, but not in the control strains of mice. Further examination of the buried food test data revealed that 3xTg-AD females had a significantly longer latency to detect the buried food than males beginning at 26 weeks of age. Overall, this study provides further validation of the 3xTg-AD mouse model of AD and supports the idea that simple olfactory testing could be part of the diagnostic process for human AD.

17 August 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
ECEmma Croushore
Emma Croushore
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
KGKelli L. Goss
Kelli L. Goss
EGElizabeth L. Geary
Elizabeth L. Geary
DGDavid Gordon
David Gordon
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the synthesis of deoxyribonucleosides and is required for DNA replication. Multiple types of cancer, including Ewing sarcoma tumors, are sensitive to RNR inhibitors or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. However, the polypharmacology and off-target effects of RNR inhibitors have complicated the identification of the mechanisms that regulate sensitivity and resistance to this class of drugs. Consequently, we used a conditional knockout (CRISPR/Cas9) and rescue approach to target RRM1 in Ewing sarcoma cells and identified that loss of the RRM1 protein results in the upregulation of the expression of multiple members of the activator protein-1 (AP-1) transcription factor complex, including c-Jun and c-Fos, and downregulation of c-Myc. Notably, overexpression of c-Jun and c-Fos in Ewing sarcoma cells is sufficient to inhibit cell growth and downregulate the expression of the c-Myc oncogene. We also identified that the upregulation of AP-1 is mediated, in part, by SLFN11, which is a replication stress response protein that is expressed at high levels in Ewing sarcoma. In addition, small-molecule inhibitors of RNR, including gemcitabine, and histone deacetylase inhibitors, which reduce the level of the RRM1 protein, also activate AP-1 signaling and downregulate the level of c-Myc in Ewing sarcoma. Overall, these results provide novel insight into the critical pathways activated by loss of RNR activity and the mechanisms of action of inhibitors of RNR. Significance: RNR is the rate-limiting enzyme in the synthesis of deoxyribonucleotides. Although RNR is the target of multiple chemotherapy drugs, polypharmacology and off-target effects have complicated the identification of the precise mechanism of action of these drugs. In this work, using a knockout-rescue approach, we identified that inhibition of RNR upregulates AP-1 signaling and downregulates the level of c-Myc in Ewing sarcoma tumors.

1 June 2025 in Cancer Research Communications
Verified
Journal Article
Open access
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
EGElizabeth L. Geary
Elizabeth L. Geary
MTMary V. Thomas
Mary V. Thomas
ECEmma Croushore
Emma Croushore
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
DGDavid Gordon
David Gordon
Histone deacetylases (HDAC) regulate diverse pathways in cancer cells. Previously, we identified that Ewing sarcoma tumors, which are caused by a translocation between the EWSR1 and FLI1 genes (EWS::FLI1), are sensitive to drugs that target DNA replication, including the RRM1 and RRM2 subunits of ribonucleotide reductase, and the ATR–checkpoint kinase 1 (CHK1)–WEE1 signaling pathway. In this study, we identified that multiple HDAC inhibitors, including fimepinostat, romidepsin, and panobinostat, downregulate the levels of the RRM1, RRM2, CHK1, and WEE1 proteins in Ewing sarcoma cells and impair DNA replication. Moreover, transcriptome analyses identified that HDAC inhibitors downregulate the expression of multiple components of the prereplication complex, including the minichromosome maintenance complex 2–7 (MCM2–7) proteins and CDT1, that are essential for genomic DNA replication. Additionally, proteomic studies identified that HDAC inhibitors also downregulate the level of the BRD4 protein, a BET bromodomain protein that regulates both the transcriptional program of the EWS::FLI1 oncoprotein and DNA replication. Overall, these results provide novel insight into the molecular mechanisms by which HDAC inhibitors target cancer cells, regulate DNA replication, and inhibit the cellular response to DNA replication stress. Significance: In this work, we identify that HDAC inhibitors broadly disrupt DNA replication and the response to replication stress in Ewing sarcoma cells by downregulating RRM1, RRM2, CHK1, and WEE1. Notably, HDAC inhibitors also reduce MCM2–7 proteins, which are essential for prereplication complex helicase function in replication initiation and elongation, and CDT1, which loads MCM2–7 onto DNA.

27 June 2025
Verified
Other
Open access
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
EGElizabeth L. Geary
Elizabeth L. Geary
MTMary V. Thomas
Mary V. Thomas
ECEmma Croushore
Emma Croushore
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
DGDavid Gordon
David Gordon
Reverse phase protein array (RPPA) data for cell lines treated with romidepsin or panobinostat compared to vehicle treatment.

27 June 2025
Verified
Other
Open access
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
EGElizabeth L. Geary
Elizabeth L. Geary
MTMary V. Thomas
Mary V. Thomas
ECEmma Croushore
Emma Croushore
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
DGDavid Gordon
David Gordon
HDAC inhibitors impair DNA replication in Ewing sarcoma cells. A, Representative cell-cycle analysis (EdU and propidium iodide) plot for EW8 cells treated with romidepsin (5 nmol/L) for 24 hours. B, Summary of EdU incorporation efficiency for additional Ewing sarcoma cell lines treated with romidepsin (5 nmol/L) for 24 hours. C, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then chromatin-bound RPA2 was assessed using immunoblotting. D, EW8 cells expressing a doxycycline-inducible shRNA targeting RPA2 were treated with doxycycline for 24 hours, and then cellular lysates were collected for immunoblotting. E and F, EW8 cells expressing a doxycycline-inducible shRNA targeting RPA2 were treated with doxycycline (1,000 ng/mL) for 24 hours, and then dose-response experiments were performed with romidepsin (E) and panobinostat (F). Cell viability was measured 72 hours after drug addition using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. G, CRISPR dependency score for CDT1 and MCM2–7 (depmap.org). H, EW8 and TC71 cells were treated with two different siRNAs targeting MCM2, and then cellular lysates were collected for immunoblotting. I, EW8 and TC71 cells were treated with siRNAs targeting MCM2, and then EdU incorporation into DNA was measured using flow cytometry. J, Kaplan–Meier analysis shows overall survival of patients with Ewing sarcoma tumors according to the expression level of CDT1 and MCM2 mRNA. P values were calculated using a two-tailed Student t test or a one-way ANOVA followed by the Dunnett multiple comparisons test. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

27 June 2025
Verified
Other
Open access
PDF file
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
EGElizabeth L. Geary
Elizabeth L. Geary
MTMary V. Thomas
Mary V. Thomas
ECEmma Croushore
Emma Croushore
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
DGDavid Gordon
David Gordon
SiRNA-mediated knockdown of HDAC1, 2, 3, and 8.